Bio-Rad Laboratories, Inc. (BIO) Stock
BIO Key Statistics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
CEO: Norman D. Schwartz. Company website
BIO — Frequently Asked Questions
What is the BIO stock price today?
Bio-Rad Laboratories, Inc. (BIO) trades at $376.41, down 1.57% on the day, as of Sep 20, 2026 15:01 UTC.
What is Bio-Rad Laboratories, Inc.'s market cap?
Bio-Rad Laboratories, Inc. has a market capitalisation of $10.13B, calculated from the live BIO share price and shares outstanding.
What is the P/E ratio of BIO?
BIO trades at a trailing P/E of 45.63, from earnings per share of $8.25 over the last twelve months.
How much revenue does Bio-Rad Laboratories, Inc. make?
Bio-Rad Laboratories, Inc. generated revenue of $2.59B over the trailing twelve months, which puts the stock at 3.91 times sales.
What is the 52-week range for BIO?
BIO has traded between $236.73 and $396.23 over the past 52 weeks, and the last price is 5.0% below that high.
Is Bio-Rad Laboratories, Inc. profitable?
Yes. Bio-Rad Laboratories, Inc. keeps 8.59% of revenue as net income over the trailing twelve months.
What is the analyst price target for BIO?
Wall Street analysts rate BIO Buy, with an average price target of $350.00, 7.0% below the current price.
What sector is Bio-Rad Laboratories, Inc. in?
Bio-Rad Laboratories, Inc. is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Who is the CEO of Bio-Rad Laboratories, Inc.?
Norman D. Schwartz is the chief executive of Bio-Rad Laboratories, Inc., which employs 7,450 people.
Where can I track BIO in real time?
QFI Terminal shows BIO with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See BIO live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open BIO in Terminal See plans